New Targeted Therapy Shows Promise for Treating Advanced NSCLC With a KRAS G12C Mutation: The ASCO Plenary Series
Read about research from the April 2024 ASCO Plenary Series, which features a study evaluating a new targeted therapy drug for people with advanced non-small cell lung cancer with a KRAS G12C mutation.